Information Provided By:
Fly News Breaks for July 31, 2018
Jul 31, 2018 | 04:52 EDT
B. Riley FBR analyst George Zavoico started Pluristem Therapeutics with a Buy rating and $4.50 price target. The company's two cell therapy product candidates could change the standard of care for unmet medical needs, Zavoico tells investors in a research note.
News For PSTI From the Last 2 Days
There are no results for your query PSTI